NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ONYX · data 2026-10-31
Onyx Biotec Ltd.
In plain words
Price: 27.5% below its 52-week high of ₹49.65.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹69 cr |
| Net profit (last 12 months) | ₹-0 cr |
| Sales growth, 3 years (yearly) | 20.7% |
| Profit growth, 3 years (yearly) | — |
At a glance
ROE -0.4%, ROCE 0.5%, operating margin 0.5%: how much profit it earns on the money it uses.
Debt/equity 0.27, Profit growth — and sales growth 20.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-0.4%).
- Thin operating margin (0.5%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
12/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 7/20: Net +₹0.46 cr bought in bulk/block deals over 90 days; 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal
- 16 Sept 26Deal Bulk deal: TUSHAR KINKER bought ₹0.46 cr 0.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Onyx Biotec Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.27.
What is the 52-week high and low of Onyx Biotec Ltd.?
The 52-week high is ₹49.65 and the 52-week low is ₹24.2.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Onyx Biotec Ltd. | ₹36 | ₹65 cr | — | — | -0.4% | 0.5% | 0.27 | -12.4% |
| Vaishali Pharma Ltd. | ₹6.42 | ₹87 cr | 19.6 | — | 6.2% | 3.6% | 0.27 | -37.1% |
| Vilin Bio Med Ltd. | ₹52.05 | ₹73 cr | 40.9 | 2.8 | 7.5% | 11.3% | 0.01 | +106.5% |
| Sunil Healthcare Ltd. | ₹61.55 | ₹70 cr | 17.7 | — | 5.9% | 6% | 0.8 | -13.3% |
| Zenith Drugs Ltd. | ₹37 | ₹63 cr | 16.1 | 0.9 | 5.5% | 9.3% | 0.75 | -40.5% |
| Vivimed Labs Limited | ₹5.53 | ₹51 cr | — | — | — | -43.6% | — | +5.3% |
Compare ONYX with VAISHALI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ONYX in NSE Scanner →